Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Blood (2019) 134 (Supplement_1): 357.

https://doi.org/10.1182/blood-2019-131939

Published: 2019

Journal Articles

Family Studies of Whim Syndrome

David C. Dale, MD, Emily Dick, BA, Merideth L. Kelley, MSc, Vahagn Makaryan, MD, Jim Connelly, MD, Audrey Anna Bolyard, RN, BS

Blood (2019) 134 (Supplement_1): 215.

https://doi.org/10.1182/blood-2019-126234

Published: 2019

Journal Articles

Mortality and Risk Factors for Bacteremia in Patients with Cutaneous T-Cell Lymphoma (CTCL) at Emory University

Pamela Allen, MDMSc, Esther Kim, Amy Ayers, MPH, Mary Jo Lechowicz, MD

Blood (2019) 134 (Supplement_1): 4043.

https://doi.org/10.1182/blood-2019-131626

Published: 2019

Journal Articles

A Case Report of the Benefit of Cannabidiol (Cannabidiol (CBD)-Predominant Medical Cannabis Preparation) in the Management of Refractory Skin Graft Vs Host Disease (GVHD)

Tsiporah B. Shore, MD, Jessy B. Ryan, ANP, Michael B. Samuel, MD

Blood (2019) 134 (Supplement_1): 5687.

https://doi.org/10.1182/blood-2019-122715

Published: 2019

Journal Articles

Safety Profile of Bone Marrow Aspiration and Biopsies Performed By the Hospitalist Procedure Service at an Academic Center: An Observational Study

Jennifer U Obasi, MD, Adrian P Umpierrez De Reguero, MD

Blood (2019) 134 (Supplement_1): 5848.

https://doi.org/10.1182/blood-2019-121444

Published: 2019

Journal Articles

Rash in Patients after T-Cell-Depleted Peripheral Blood Stem Cell Transplantation: Eosinophilia and Pruritus Do Not Distinguish Acute Graft-Versus-Host Disease from Drug Rash

Skylar A Klager, MS, Sean M Devlin, PhD, Margaret Hannum, MS, Ann A. Jakubowski, MD PhD, Alina Markova, MD

Blood (2018) 132 (Supplement 1): 4570.

https://doi.org/10.1182/blood-2018-99-110307

Published: 2018

Journal Articles

Autoimmune Neutropenia of Infancy- Unexpected Prevalence of Pseudomonas Skin Infections

Joanne Yacobovich, MD, Neta Aviran Dagan, MD, Tracie Goldberg, MD, Orna Steinberg Shemer, MD MSc, Hannah Tamary, MD

Blood (2018) 132 (Supplement 1): 4940.

https://doi.org/10.1182/blood-2018-99-113408

Published: 2018

Journal Articles

Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study

Anne Calleja, Sandra De Barros, Camille Vinson, PharmD, Caroline Protin, MD, Lucie Oberic, MD, Fanny Gallais, Melanie White-koning, Etienne Chatelut, Christian Recher, MD PhD, Sarah Cadot, PhD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Fabien Despas, PharmD, PhD

Blood (2018) 132 (Supplement 1): 3960.

https://doi.org/10.1182/blood-2018-99-116532

Published: 2018

Journal Articles

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

David Dale, MD, Audrey Anna Bolyard, RN, BS, Emily Dick, BA, Merideth L. Kelley, MS, Vahagn Makaryan, MD, Ramsey Johnson, MSM, Lu Gan, MD PhD, Sudha Parasuraman, MD

Blood (2017) 130 (Supplement 1): 995.

https://doi.org/10.1182/blood.V130.Suppl_1.995.995

Published: 2017

Journal Articles

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

Steven P Treon, MDPhDFRCP, Kirsten Meid, MPH, Joshua Gustine, Kurt S. Bantilan, MPH, Toni Dubeau, NP, Patricia Severns, NP, Guang Yang, PhD, Lian Xu, Christopher Patterson, MAcc, Irene M Ghobrial, MD, Jacob Laubach, MD, Zachary Hunter, PhD, Jorge J. Castillo, MD, Maria L. Palomba, MD, Ranjana H. Advani, MD

Blood (2017) 130 (Supplement 1): 2766.

https://doi.org/10.1182/blood.V130.Suppl_1.2766.2766

Published: 2017

Journal Articles

Leukocyte Adhesion Deficiency-I (LAD-I): A Comprehensive Review of Published Cases

Sanchali Kasbekar, PharmD, Juan Bueren, PhD, Adrian J Thrasher, MD PhD FMedSci, Donald B Kohn, MD, Julian Sevilla, MD PhD, Jonathan D Schwartz, MD, Elena Almarza, PhD

Blood (2017) 130 (Supplement 1): 4821.

https://doi.org/10.1182/blood.V130.Suppl_1.4821.4821

Published: 2017

Journal Articles

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

Robert W. Chen, MD, Joycelynne M. Palmer, PhD, Leslie Popplewell**, MD, Jessica Alluin, Pritsana Chomchan, Auayporn P. Nademanee, MDBS, Tanya Siddiqi, MD, Nicole Tsai, Fay Zuo, Rosie Abary, Ji-lian Cai, Steven T. Rosen, MD, Stephen J. Forman, MD FACP, Larry W Kwak, MDPhD, Leona Holmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4515.

https://doi.org/10.1182/blood.V130.Suppl_1.4515.4515

Published: 2017

Journal Articles

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Kamel Laribi, Stéphanie Poulain, MD, Lise Willems, MD, Fatiha Merabet, Charles Herbaux, Damien Roos-Weil, Alix Baugier de Materre, Xavier Roussel, Sabine Tricot, Jehan Dupuis, MD, Ronan Le Calloch, Benoit Bareau, Marie C Bene, PharmD,DPhil, Veronique Leblond

Blood (2017) 130 (Supplement 1): 4046.

https://doi.org/10.1182/blood.V130.Suppl_1.4046.4046

Published: 2017

Journal Articles

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Steven M. Horwitz, MD, Mehdi Hamadani, MD, Michelle A. Fanale, MD, Jay Feingold, MD PhD, Alexander I Spira, MD, Paul A Fields, MD PhD, Tobias Menne, MD PhD, Anand Karnad, MD, Alison J. Moskowitz, MD, Catherine Hildyard, MRCP, BA, Shui He, PhD, Joseph Boni, PhD, Graham Collins, MD PhD

Blood (2017) 130 (Supplement 1): 1510.

https://doi.org/10.1182/blood.V130.Suppl_1.1510.1510

Published: 2017

Journal Articles

Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Naval Daver, MD, Guillermo Garcia-Manero, MD, Sreyashi Basu, PhD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Elias J. Jabbour, MD, Sherry Pierce, BSN, BA, Jing Ning, PhD, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Steven M. Kornblau, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Carlos E Bueso-Ramos, MD PhD, Juliana Elisa Hidalgo Lopez, MD, Jorge Blando, DVM, James Allison, PhD, Hagop M. Kantarjian, MD, Padmanee Sharma, MD PhD

Blood (2016) 128 (22): 1641.

https://doi.org/10.1182/blood.V128.22.1641.1641

Published: 2016

Journal Articles

Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA

Blood (2015) 126 (23): 1946.

https://doi.org/10.1182/blood.V126.23.1946.1946

Published: 2015

Journal Articles

Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation

Robert Chen, Joycelynne Palmer, PhD, Leona Holmberg, Jessica Alluin, Pritsana Chomchan, PhD, Leslie L. Popplewell, MD, Tanya Siddiqi, MD, Sandra H. Thomas, PhD, Kathryn Irenze, Auayporn P. Nademanee, MD, Ricardo Spielberger, MD, John J Rossi, Steven T. Rosen, MD, Larry W. Kwak, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 1961.

https://doi.org/10.1182/blood.V126.23.1961.1961

Published: 2015

Journal Articles

Impairment of IL-17 Immunity to Candida and IFN-g Immunity to Mycobacterium in Humans with Bi-Allelic Rorc mutations

Satoshi Okada, MD PhD, Janet Markle, PhD, Masao Kobayashi, MD PhD, Jacinta Bustamante, MD PhD, Jean-Laurent Casanova, MD PhD

Blood (2015) 126 (23): 205.

https://doi.org/10.1182/blood.V126.23.205.205

Published: 2015

Journal Articles

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Susi Snitzler, RN, Olga Levina, RN, Tong (Trina) Wang, RN, Lisa W Le, MSc, Harminder Paul, Ellen Nong Wei, Anthea Lau, Michelle Queau, James B Johnston, MD, Suzanne Trudel, MD, Deborah A Smith

Blood (2015) 126 (23): 1742.

https://doi.org/10.1182/blood.V126.23.1742.1742

Published: 2015

Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD

Blood (2014) 124 (21): 3097.

https://doi.org/10.1182/blood.V124.21.3097.3097

Published: 2014

NARROW

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Family Studies of Whim Syndrome

Mortality and Risk Factors for Bacteremia in Patients with Cutaneous T-Cell Lymphoma (CTCL) at Emory University

A Case Report of the Benefit of Cannabidiol (Cannabidiol (CBD)-Predominant Medical Cannabis Preparation) in the Management of Refractory Skin Graft Vs Host Disease (GVHD)

Safety Profile of Bone Marrow Aspiration and Biopsies Performed By the Hospitalist Procedure Service at an Academic Center: An Observational Study

Rash in Patients after T-Cell-Depleted Peripheral Blood Stem Cell Transplantation: Eosinophilia and Pruritus Do Not Distinguish Acute Graft-Versus-Host Disease from Drug Rash

Autoimmune Neutropenia of Infancy- Unexpected Prevalence of Pseudomonas Skin Infections

Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

Leukocyte Adhesion Deficiency-I (LAD-I): A Comprehensive Review of Published Cases

Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma

The Bendamustine Plus Rituximab Regimen Is Active and Safe in Previously Untreated Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

Phase IB/II Study of Lirilumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML)

Skin Immune Stimulation By Infections and Drug Toxicities during Induction and/or Consolidations Increases Incidence of Skin Acute Graft Versus Host Disease in Acute Myeloid Leukemia: A Study on Behalf of SFGM-TC and ALFA

Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation

Impairment of IL-17 Immunity to Candida and IFN-g Immunity to Mycobacterium in Humans with Bi-Allelic Rorc mutations

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only